- Home
- WBX vs ALXO Comparison
WBX vs ALXO Comparison
Compare WBX & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- ALXO
- Stock Information
- Founded
- WBX 2015
- ALXO 2015
- Country
- WBX Spain
- ALXO United States
- Employees
- WBX N/A
- ALXO N/A
- Industry
- WBX Industrial Specialties
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- WBX Consumer Discretionary
- ALXO Health Care
- Exchange
- WBX Nasdaq
- ALXO Nasdaq
- Market Cap
- WBX 118.0M
- ALXO 102.3M
- IPO Year
- WBX N/A
- ALXO 2020
- Fundamental
- Price
- WBX $6.16
- ALXO $1.57
- Analyst Decision
- WBX Buy
- ALXO Strong Buy
- Analyst Count
- WBX 4
- ALXO 6
- Target Price
- WBX $10.50
- ALXO $3.30
- AVG Volume (30 Days)
- WBX 40.7K
- ALXO 791.9K
- Earning Date
- WBX 11-05-2025
- ALXO 11-06-2025
- Dividend Yield
- WBX N/A
- ALXO N/A
- EPS Growth
- WBX N/A
- ALXO N/A
- EPS
- WBX N/A
- ALXO N/A
- Revenue
- WBX $173,788,608.00
- ALXO N/A
- Revenue This Year
- WBX N/A
- ALXO N/A
- Revenue Next Year
- WBX $46.25
- ALXO N/A
- P/E Ratio
- WBX N/A
- ALXO N/A
- Revenue Growth
- WBX N/A
- ALXO N/A
- 52 Week Low
- WBX $3.69
- ALXO $0.40
- 52 Week High
- WBX $23.80
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- WBX 68.18
- ALXO 50.75
- Support Level
- WBX $6.00
- ALXO $1.83
- Resistance Level
- WBX $7.83
- ALXO $2.27
- Average True Range (ATR)
- WBX 0.54
- ALXO 0.22
- MACD
- WBX 0.17
- ALXO -0.04
- Stochastic Oscillator
- WBX 51.46
- ALXO 29.93
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.